The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 8 of the 288 sources its claims cite were checked for support.
Defining the commercial determinants of health: a systematic review
Open accessAbstract
Background: Despite increasing attention to the social determinants of health in recent decades, globally there is an unprecedented burden from non-communicable diseases (NCDs). Recently, the corporate and commercial conditions associated with these, commercial determinants of health (CDoH), have also begun to receive attention. This research aims to articulate the CDoH as described in the literature, summarize substantive findings, and assess strengths and limitations of current literature. Methods: Systematic review of formal (Medline, EMBASE, Scopus, Global Health) and grey literature (database, Google Advanced, targeted website, citation searching). Searching identified 125 texts for full-text review, with 33 included for final review. Data extracted were analyzed thematically. Results: The dynamics constituting CDoH include broad facilitators such as globalization of trade, corporate structures, and regulatory systems, articulation of social and economic power, neoliberal and capitalist ideologies; additional elements include corporate activities such as marketing, corporate political activities, corporate social responsibility, extensive supply chains, harmful products and production, and issues of accessibility. These contribute significantly to worsened global health outcomes. Conclusions: Literature describing effects of macro conditions and corporate activities on health could usefully utilize CDoH terminology. Facilitation via revised, consistent and operational definition of CDoH would assist. Social, political, commercial and economic structures and relations of CDoH are under-theorized. Systematic approaches to identifying, describing, and disrupting these are required to improve global health.
Overview
CoChat Summary
TL;DR
This systematic review synthesizes literature on the commercial determinants of health (CDoH), finding no widely accepted definition and a field that is largely descriptive and conceptual. It maps macro-level conditions, corporate activities, and health harms, and calls for greater definitional precision and systematic action.
Key findings
- No widely accepted CDoH definition was apparent; most texts (n = 19) provided no definition, and three prominent definitions were identified: West and Marteau’s “factors that influence health which stem from the profit motive”; Kickbusch et al.’s “strategies and approaches used by the private sector to promote products and choices that are detrimental to health”; and Kosinska and Ostlin’s broader working definition about an inherent tension between commercial and public health objectives for a good or service.
- CDoH were described as including macro-level facilitators such as globalization of trade, corporate structures, regulatory systems, economic and political power, and neoliberal/capitalist ideologies, alongside corporate activities including marketing, corporate political activities, corporate social responsibility, supply chains, harmful products/production, and accessibility.
- Downstream consequences were consistently described as premature death and disability associated with NCDs/chronic diseases, including cancers, obesity/overweight, cardiovascular diseases, COPD, high cholesterol, diabetes, cirrhosis, injuries, and harms to planetary health.
- The literature most often referenced the food industry, followed by tobacco and alcohol; pharmaceutical, automotive, firearms, mining, and gambling industries were discussed less. Authors appraised existing efforts to address CDoH as inadequate and emphasized the need for new approaches or a paradigm shift.
Methods
- Systematic review conducted per PRISMA; no protocol was registered or published. Searches covered Medline, EMBASE, Scopus, Global Health; grey literature databases, Google Advanced, targeted organization websites, and backward/forward citation searching.
- Inclusion criteria covered peer-reviewed and grey literature providing a definition/description of CDoH drivers, mechanisms, or outcomes; original studies, reviews, commentaries, editorials, discussion papers, books/chapters, reports, web articles/resources, and conceptual works. Exclusions included non-English literature, non-human data, modelling/clinical/laboratory findings without underlying determinants, and surveillance/intervention descriptions without underlying determinants.
- Data extracted included author/date, title, publisher/source, publication type, evidence type, underpinning theories/frameworks, and CDoH terms used; analysis was thematic and inductive. The abstract reports 125 texts for full-text review and 33 included; the results section reports 32 texts included for final review.
Limitations
- The paper states: the narrow searching frame may have missed peripheral CDoH concepts; the working definition used for initial planning may be a limitation; English-only inclusion means high-income country perspectives frame much of the literature; and grey literature searching has inherent limitations including volume and search-engine “filter bubble.”
- The paper states the field is emerging and underdeveloped, with limited capacity to synthesize substantive findings; most included literature was descriptive/conceptual, lacked systematic analysis and original data, and would be appraised as low quality by traditional measures.
- Evident from the text: the abstract and results report different final inclusion counts (33 vs 32), indicating an internal inconsistency; the review also notes no widely accepted definition and inconsistent application of CDoH terminology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
4 Valid · 4 Not valid · 88 Not checked · 37 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Most commonly, CDoH were described as resulting from expressions of economic and political power wielded by large corporate entities, described as “powerful economic operators” [16, 19, 30, 35].”
§ Defining the commercial determinants of health: a systematic review > Results > Macro-level conditions constituting CDoH
What the sources say
- Supportedcites [16] Buse K, Tanaka S, Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Health. 2017;13(1):34. source
The Background section of Buse, Kent & Tanaka (2017) uses exactly the descriptor the claim attributes to it: 'Efforts to prevent noncommunicable diseases go against the business interests of powerful economic operators' (quoting the WHO Director-General, ref 25), immediately followed by the scale of corporate profits relative to public health budgets. The paper elsewhere frames the commercial determinants in terms of corporate economic and political power — 'lobbying by powerful multinational corporations who succeeded in shaping international law to protect their markets' and Table 1 'Corporate political activity' (Findings > Public regulation of the private sector), plus trade/investment policies that 'diminished the policy space' for governments. The only nuance is that the phrase 'powerful economic operators' is quoted from the WHO DG rather than coined by the authors, and the 'most commonly' comparative is the citing review's synthesis across its multiple sources. (LLM, conf=0.82)
- Supportedcites [19] Kickbusch I, Allen L, Franz C. The commercial determinants of health. Lancet Glob Health. 2016;4(12):e895–e6. source
Our copy of Kickbusch, Allen & Franz (2016) opens by quoting WHO Director-General Margaret Chan that "efforts to prevent non-communicable diseases go against the business interests of powerful economic operators", so the quoted phrase is genuinely this paper's. The body of the Comment frames CDoH exactly as the claim describes: it notes "critical public health analysis of the power of the corporate sector", attributes the field to factors "boosting the power of large companies" (rising demand, market coverage, internationalisation of trade and investment), and sets out corporate influence exerted through economic channels (marketing, supply chains) and a political one (lobbying, "which can impede policy barriers"). The only element not stated by this source is the comparative "most commonly", which is the citing authors' synthesis across the four pooled references rather than an assertion attributed to this paper alone. (LLM, conf=0.85)
- Supportedcites [30] Kickbusch I, Szabo MMC. A new governance space for health. Glob Health Action. 2014;7. https://doi.org/10.3402/gha.v7.23507. source
In 'Global governance for health' our copy ties the commercial determinants of health directly to 'the increasing influence of transnational companies and their products on population health' and reproduces the term 'powerful economic operators' (quoting the WHO Director-General, ref. 7) in that same passage, alongside the definition of these drivers as 'the factors that influence health which stem from the profit motive'. The 'Defining global health and global governance' section adds the political-power element ('market power readily translates into political power'; pressure from trans-national private companies on Member States), and the Conclusions frame contestations of power and interests as translating into political and commercial determinants of health. The 'most commonly' frequency judgement is the citing authors' synthesis across their four citations rather than a claim this commentary paper makes, but the paper itself clearly characterises CDoH in these terms, so the substance attributed to it is supported; the phrase 'powerful economic operators' is reported and relied on here (credited to WHO ref. 7), not merely deferred to another work. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Power imbalances were described both between corporations (large, for-profit, often trans-national entities) and governments with conflicting interests [30, 33, 34, 39, 43]”
§ Defining the commercial determinants of health: a systematic review > Results > Macro-level conditions constituting CDoH
What the sources say
- Supportedcites [30] Kickbusch I, Szabo MMC. A new governance space for health. Glob Health Action. 2014;7. https://doi.org/10.3402/gha.v7.23507. source
In 'Defining global health and global governance' the paper states that resource-strong non-state actors have grown in influence and 'exert political pressure on donor and recipient countries', citing WHA66 remarks that 'the pressure from trans-national private companies on Member States was never stronger', and Dr. Chan's 'market power readily translates into political power. Few governments prioritize health over big business'. The 'Global governance for health' section ties this to 'increasing influence of transnational companies' whose profit motive ('commercial determinants of health') conflicts with NCD prevention, and the paper elsewhere notes 'new power relationships' and the need for 'firewalls and conflict of interest strategies' (Fig. 2 discussion). Together these describe a power imbalance between large, trans-national, for-profit corporations and governments with conflicting interests, so the paraphrase is supported; the strongest phrasing is voiced via the WHO Director-General's quotations, which the paper reports and relies on. (LLM, conf=0.85)
- Check pendingcites [33] Madureira Lima J, Galea S. Corporate practices and health: A framework and mechanisms. Global Health. 2018;14(1):21-32. source
- Supportedcites [34] McKee M, Stuckler D. Revisiting the corporate and commercial determinants of health. Am J Public Health. 2018;108(9):1167–70. source
The Abstract of our copy states the point directly: 'An effective response to the corporate and commercial determinants of health must address the power imbalance between global corporations, which are accountable only to their owners and shareholders, and governments, which are accountable to their citizens.' The 'Setting the Rules' section frames the corporate–government relationship as a paradox (corporations railing against regulation while depending on governments to protect intellectual property and enforce contracts), i.e. conflicting interests, and the paper repeatedly characterises the actors as large global/multinational, shareholder-accountable firms (Introduction, 'The Changing Nature of Corporate Power'). (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Trade agreements and liberalization were described as contributing to worsened health outcomes [16, 24, 31, 34, 36, 41, 43, 44].”
§ Defining the commercial determinants of health: a systematic review > Results > Macro-level conditions constituting CDoH
What the sources say
- Partly supportedcites [16] Buse K, Tanaka S, Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Health. 2017;13(1):34. sourceExperimental — accuracy not yet measured
Our copy does link trade agreements to NCD risk, but at a different level of specificity and with hedging: in Findings > Public regulation of the private sector it states that challenges to public regulation 'are likely to increase with the impact of new trade and investment policies (free trade agreements) which have diminished the policy space within which Governments can exert control over NCD-related measures' [77, 78], and Table 1 notes industry use of bilateral investment treaties to 'challenge states' policymaking authority'. That is an erosion-of-policy-space / prospective argument about prevention, not a statement that trade agreements and liberalization contributed to worsened health outcomes; the Background explicitly declines to attribute specific NCD outcomes to commercial drivers, and the Discussion's 'escalation of transnational commercial activities as a determinant of poor health' refers to commercial activity generally rather than to trade liberalization. So the policy-space part is supported while the direct 'worsened health outcomes' attribution is not. (LLM, conf=0.68)
- Check pendingcites [24] Franz C, Kickbusch I. The capital-NCD-nexus: the commercial determinants of health and global capital flows. Eurohealth (Lond). 2018;24(3):21–5.
- Check pendingcites [31] Knai C, Petticrew M, Mays N, Capewell S, Cassidy R, Cummins S, et al. Systems thinking as a framework for analyzing commercial determinants of health. Milbank Q. 2018;96(3):472–98. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Corporate rights, including intellectual property rights, were described as presenting challenges to many interventions that could benefit public health [16, 33, 34, 43].”
§ Defining the commercial determinants of health: a systematic review > Results > Macro-level conditions constituting CDoH
What the sources say
- Supportedcites [16] Buse K, Tanaka S, Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Health. 2017;13(1):34. source
In 'Findings > Public regulation of the private sector' our copy states that the 1994 WTO adoption of TRIPS — 'which dictates how states should regulate intellectual property protection' — resulted from multinational corporate lobbying 'to protect their markets', and that the tobacco industry uses bilateral investment treaties to 'challenge states' policymaking authority'. The same section says public regulation 'presents the major challenge of enforceable public authority over the private sector' and that new trade and investment policies 'have diminished the policy space within which Governments can exert control over NCD-related measures'. Together these support the attributed content that corporate legal rights, including IP rights, impede a range of public-health-benefiting interventions; the paper does not use the exact phrase 'corporate rights', but the substance is stated. (LLM, conf=0.80)
- Check pendingcites [33] Madureira Lima J, Galea S. Corporate practices and health: A framework and mechanisms. Global Health. 2018;14(1):21-32. source
- Supportedcites [34] McKee M, Stuckler D. Revisiting the corporate and commercial determinants of health. Am J Public Health. 2018;108(9):1167–70. source
The 'Commodifying Knowledge' section states that corporations extend intellectual property, e.g. patented genetically modified foods creating dependence among indigenous farmers, and lobby 'for ever greater intellectual property protection that impedes market entry of those who could make those medicines affordable,' while also demanding state mechanisms to enforce these property rights. The 'Political, Economic, and Social Rights' section adds that they promote international trade deals 'that challenge national policies through investor–state dispute resolution procedures' and can 'slow, or even reverse, the expansion of universal health coverage,' with the earlier section noting secret ISDS tribunals and trade liberalization (e.g. TPP). Together these support the attributed point that corporate rights, including intellectual property rights, pose challenges to health-promoting interventions; the citing sentence is a broad paraphrase across several domains rather than a single quoted finding. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most (n = 19) texts provided no definition.”
§ Defining the commercial determinants of health: a systematic review > Results > Defining commercial determinants
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
26 more claims
Create a free account to see all 133 claims and to verify the 248 references still open.
- Probably not a substantial claim. 91
- It may state two separate claims as one. 33
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Defining the commercial determinants of health: a systematic review > Abstract > Methods
“Searching identified 125 texts for full-text review, with 33 included for final review.”
§ Defining the commercial determinants of health: a systematic review > Results > Literature selection
“Thirty-two texts were included for final review (see Fig. 1).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Defining the commercial determinants of health: a systematic review > Methods > Literature selection
“Hastings (2015) [9] | Public health and the value of disobedience | Public Health (Journal article)”
§ Defining the commercial determinants of health: a systematic review > References
“9. Hastings G Public health and the value of disobedience Ann Nutr Metab 2015 129 66 67 26027449”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Defining the commercial determinants of health: a systematic review > Results > Proposals for harm minimization, and hierarchy of harmful industries
“Wiist [39] took this further, suggesting the need to restructure corporate entities, repeal corporate charters, remove corporate personhood rights, and restore liability to shareholders and officials.”
§ Defining the commercial determinants of health: a systematic review > References
“39. Thorn M Addressing power and politics through action on the commercial determinants of health Health Promot J Austr 2018 29 3 225 227 30511490”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Defining the commercial determinants of health: a systematic review > Methods > Literature selection
“International Federation of Medical Students’ Associations, Team of Officials (2017) [26]”
§ Defining the commercial determinants of health: a systematic review > References
“26. International Federation of Medical Students' Associations IFMSA Policy Non-Communicable Diseases 2015”
Citations
Cites
Tong, A., Sainsbury, P., & Craig, J. (2007) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzm042 · Cited by 42,509
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Social determinants of health inequalities
Marmot, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71146-6 · Cited by 5,086
Moodie, R., Stuckler, D., Monteiro, C., Sheron, N., Neal, B., Thamarangsi, T., Lincoln, P., & Casswell, S. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62089-3 · Cited by 1,663
Godin, K., Stapleton, J., Kirkpatrick, S. I., Hanning, R. M., & Leatherdale, S. T. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0125-0 · Cited by 959
The commercial determinants of health
Kickbusch, I., Allen, L., & Franz, C. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30217-0 · Cited by 782
Health in the sustainable development goals: ready for a paradigm shift?
Buse, K., & Hawkes, S. (2015) · Globalization and Health · doi:10.1186/s12992-015-0098-8 · Cited by 373
Mialon, M., Swinburn, B., & Sacks, G. (2015) · Obesity Reviews · doi:10.1111/obr.12289 · Cited by 318
Revisiting the corporate and commercial determinants of health
McKee, M., & Stuckler, D. (2018) · American Journal of Public Health · doi:10.2105/ajph.2018.304510 · Cited by 281
Systems Thinking as a Framework for Analyzing Commercial Determinants of Health
KNAI, C., PETTICREW, M., MAYS, N., CAPEWELL, S., CASSIDY, R., CUMMINS, S., EASTMURE, E., FAFARD, P., HAWKINS, B., JENSEN, J. D., et al. (2018) · The Milbank Quarterly · doi:10.1111/1468-0009.12339 · Cited by 199
Research works printed but not linked: 3
- Kosinska M, Ostlin P. Building systematic approaches to intersectoral action in the WHO European region. Public Health Panorama. 2016;2(2):124–9.
- United Nations Department of Economic and Social Affairs, United Nations Industrial Development Organization. Report of the expert meeting in preparation for HLPF 2017 on Readying institutions and policies for integrated approaches to implementation of the 2030 Agenda. Vienna: United Nations Department of Economic and Social Affairs, United Nations Industrial Development Organization; 2016.
- Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of in terventions. Chichester: Wiley-Blackwell; 2008.
Cited by
Defining and conceptualising the commercial determinants of health
Gilmore, A. B., Fabbri, A., Baum, F., Bertscher, A., Bondy, K., Chang, H.-J., Demaio, S., Erzse, A., Freudenberg, N., Friel, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00013-2 · Cited by 758
Social media and the spread of misinformation: infectious and a threat to public health
Denniss, E., & Lindberg, R. (2025) · Health Promotion International · doi:10.1093/heapro/daaf023 · Cited by 252
Knai, C., Petticrew, M. P., Capewell, S., Cassidy, R., Collin, J., Cummins, S., Eastmure, E., Fafard, P., Fitzgerald, N., Gilmore, A., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-003543 · Cited by 239
Power analysis in health policy and systems research: a guide to research conceptualisation
Topp, S. M., Schaaf, M., Sriram, V. M., Scott, K., Dalglish, S. L., Nelson, E. M., Rajasulochana, S. R., Mishra, A., Asthana, S., Parashar, R., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-007268 · Cited by 163
Hambleton, I. R., Caixeta, R. D. B., Jeyaseelan, S. M., Luciani, S., & Hennis, A. J. M. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100483 · Cited by 143
Metadata
- Authors
- de Lacy-Vawdon, C., & Livingstone, C.
- Affiliations
- Monash University (AU)
- Corresponding author
- Livingstone, Charles
- ORCID
- Livingstone, Charles
- Venue
- BMC Public Health
- Published
- 2020-06-29
- Volume
- 20
- Issue
- 1
- Pages
- 1022-1022
- ISSN
- 1471-2458 (ISSN-L)
- PMC
- PMC7325018
- OpenAlex
- W3037272524
- Cited by
- 200
- References
- 50
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 44 · 2023: 30 · 2022: 30 · 2021: 21 · 2020: 2
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Public Health (publishedVersion, cc-by)
- Monash University Research Portal (Monash University) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Australian Government
- Monash University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Public Health Policies and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Public Health Policies and Education
- Social Sciences › Health › Public Health and Social Inequalities
- Keywords
- commercial determinants of health, non-communicable diseases, corporate influence on health, neoliberalism, trade globalization, corporate marketing, corporate political activity, corporate social responsibility, supply chain, harmful products, health disparities, social determinants of health, health policy
- MeSH terms
- Noncommunicable Diseases, Commerce, Humans, Politics, Social Responsibility, Global Health, Internationality, Social Determinants of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the commercial determinants of health: a systematic review. https://app.cochat.ai/papers/10.1186/s12889-020-09126-1
- The paper
- de Lacy-Vawdon, C., & Livingstone, C. (2020). Defining the commercial determinants of health: a systematic review. BMC Public Health. https://doi.org/10.1186/s12889-020-09126-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
